Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-11 23:30:56 EDT

Explore

PostsPeople
LatestRanked
Load more
@practicaldiabetic.bsky.socialOct 2, 2026, 8:17 AM

Dual hormone system vs MDI and normal AID/Looping. No significant improvement compared to AID and a lot of dropouts because of the high maintenance of the dual hormone system. No clear benefit for dual hormone systems. #EASD2026 #dedoc⁰

@thelancetendo.bsky.socialOct 2, 2026, 8:14 AM

Despite strong evidence that early detection and continuous management reduce morbidity and mortality, many health systems face persistent gaps in diagnosis, treatment, and follow-up of people with diabetes www.thelancet.com/journals/lan...
#diabetes #primary #care
#EASD2026

#MedSky #EndoSky

@springermedicine.comOct 2, 2026, 8:02 AM

From #EASD2026 - Mauritius has become the first country to demonstrate a decrease in the prevalence of type 2 diabetes and intermediate hyperglycemia using the oral glucose tolerance test.

Full story 👉️ buff.ly/hZM05mX

#MedNews

@thelancetendo.bsky.socialOct 2, 2026, 8:00 AM

Type 2 #diabetes is a heterogeneous, progressive chronic condition for which management has traditionally focused on glycaemic control and cardiovascular risk factors, rather than focusing on altering long-term disease trajectory www.thelancet.com/journals/lan...
#disease #modification
#EASD2026

@isletbiologylab.bsky.socialOct 2, 2026, 7:55 AM

Our PhD student Sara Cortell and our PI Laura Marroqui are still on the ground at #EASD2026! 🔬
Representing the lab until the very last minute! 💪🏼

@easdnews.bsky.socialOct 2, 2026, 7:50 AM

Day4️⃣of #EASD2026 in Milan 🇮🇹: award lectures, new clinical trial data & hundreds of abstract presentations.

🎥 Missed something? Watch our Day 4 #highlights video 👇

Stay connected via the EASD Society App & follow EASD TV for interviews & insights.

www.linkedin.com/feed/update/...

@easdnews.bsky.socialOct 2, 2026, 7:30 AM

🔬 Don’t miss this important session! Join Prof. Chantal Mathieu for a Lab Talk at #EASD2026.

📅 2 Oct |🕙10:15 - 10:45 CEST | 📍 Arena

Hear about her #lab, her #research & how she leads her team.

Make sure to join the conversation in the Arena! It's going to be a great one!

#Diabetes #LabTalk

@practicaldiabetic.bsky.socialOct 2, 2026, 6:55 AM

Growing evidence that Semaglutide is effective at addressing addictions. #EASD2026 #dedoc⁰

@practicaldiabetic.bsky.socialOct 2, 2026, 6:51 AM

Not all GLP-1s are created equal. Sitting in on talk where they are saying the success of Semaglutide and Tirzepatide is the addition of a fatty acid molecule to stop it being cleared quickly from the body which happens to other GLP-1s such as those from diet #EASD2026 #dedoc⁰

@eudiabetesforum.bsky.socialOct 2, 2026, 6:24 AM

❤️ Early detection saves lives.

This week, EU Health Commissioner Olivér Várhelyi launched the first-ever EU Screening Week at #EASD2026.

The message is simple: get checked, know your numbers and take control of your health. 🩺

EUDF is proud to support this important prevention campaign.

@thelancetendo.bsky.socialOct 2, 2026, 6:19 AM

S Alice Longa & Cate Speake comment on:
#IL-2 and immunoregulatory therapies in newly diagnosed type 1 #diabetes thelancet.com/journals/lan...
#T1D
#EASD2026

#MedSky #EndoSky

@thelancetendo.bsky.socialOct 2, 2026, 6:19 AM

New—Efficacy and safety of low-dose #IL-2 in people with newly diagnosed type 1 #diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial thelancet.com/journals/lan...
#T1D
#EASD2026

#MedSky #EndoSky

@wilayahmy.bsky.socialOct 2, 2026, 3:33 AM

Sinocare Brings Connected Diabetes and Chronic Disease Management Portfolio to EASD 2026 #DiabetesManagement #ChronicDisease #HealthcareInnovation #EASD2026 #MedicalTechnology

@medpagetoday.comOct 2, 2026, 1:44 AM

An investigational dual GIP/GLP-1 agonist achieved modest weight loss in adults with type 2 diabetes and obesity, the phase III SYNCHRONIZE-2 trial showed, but tolerability remains a concern. @easdnews.bsky.social #EASD2026
https://www.medpagetoday.com/meetingcoverage/easd/123234

@leglesszebra.bsky.socialOct 1, 2026, 8:13 PM

Been a very busy and very interesting week at #EASD2026 - and thrilled to discover a negroni bar outside the congress centre. Perfect after a long busy day and a warm night!

Lynda (woman, long dark red hair) sitting outside congress centre with EASD 2026 banner. Holding a tall negroni spritzer!
@medpagetoday.comOct 1, 2026, 6:59 PM

Orforglipron (Foundayo) was able to claim cardiovascular safety based on the ACHIEVE-4 trial, though heart benefits remain unproven. @easdnews.bsky.social #EASD2026
https://www.medpagetoday.com/meetingcoverage/easd/123204

@midgardfinance.comOct 1, 2026, 3:30 PM

💉 #pharma #EASD2026

🇺🇸 $LLY #eloralintide added 8.5 points of weight loss to tirzepatide in type 2 diabetes: 23.3% vs 14.8%, 48 wk.

🇩🇰 $NOVO #CagriSema: 4.0 added to semaglutide, 14.2% vs 10.2%, 68 wk. One-molecule #zenagamtide: 14.6%, 36 wk.

Separate trials.

midgardfinance.com/diabetes/

Chart titled "Amylin added 8.5 points to tirzepatide, 4.0 to semaglutide". Three rows, each a separate trial in adults with type 2 diabetes, showing the average weight loss at the top dose as estimated for people staying on treatment. Top row, Lilly, two molecules, phase 2b, 48 weeks: a grey point for tirzepatide 15 mg alone at 14.8 per cent joined to a red point for the same dose with eloralintide 9 mg at 23.3 per cent. Middle row, Novo, two molecules, the REIMAGINE 2 trial, phase 3, 68 weeks: a grey point for semaglutide 2.4 mg alone at 10.2 per cent joined to a blue point for the same dose with cagrilintide 2.4 mg at 14.2 per cent. Bottom row, Novo, one molecule, phase 2, 36 weeks: a single blue point for zenagamtide 40 mg at 14.6 per cent, marked as having no arm without amylin, because both actions are in the same molecule. The rows are not a ranking: the trials differ in length, stage and participants, and only the gap inside a row compares like with like.
@springermedicine.comOct 1, 2026, 3:15 PM

With #EASD2026 soon coming to a close, we bring you the key updates and latest advances in #diabetes research, treatment, and care from this year's meeting.

👉️ buff.ly/7GIjfiy

#MedSky

@thelancet.comOct 1, 2026, 3:07 PM

Presented at #EASD2026—Mauritius is the first country to show a decreasing prevalence of diabetes and intermediate hyperglycaemia over time, using the objective, gold standard OGTT-based diagnostic criteria recommended by WHO. More in @thelancetendo.bsky.social: spkl.io/633217pvTl

Section of the first page of an article published in The Lancet Diabetes & Endocrinology entitled "Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study".
@arc-em.bsky.socialOct 1, 2026, 3:06 PM

A new review published in @thelancetendo.bsky.social argues primary care is fundamental to tackling the rising number of people living with diabetes worldwide.

Our researchers are among the authors, and it was presented today at #EASD2026 in Milan.

Read more:
🔗 arc-em.nihr.ac.uk/news/primary...